Close Menu

NEW YORK (GenomeWeb) – MDxHealth said today that the New York State Department of Health has approved its SelectMDx test for prostate cancer. The approval completes MDxHealth's state licensing requirements for SelectMDx, allowing the firm to offer the liquid biopsy test in all 50 US states.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.